Fetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and Prevention
Open Access
- 12 November 2015
- journal article
- review article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 64 (4) , 279-290
Abstract
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a relatively rare condition (1/1000–1/2000) that was granted orphan status by the European Medicines Agency in 2011. Clinical consequences of FNAIT, however, may be severe. A thrombocytopenic fetus or new-born is at risk of intracranial hemorrhage that may result in lifelong disability or death. Preventing such bleeding is thus vital and requires a solution. Anti-HPA1a antibodies are the most frequent cause of FNAIT in Caucasians. Its pathogenesis is similar to hemolytic disease of the newborn (HDN) due to anti-RhD antibodies, but is characterized by platelet destruction and is more often observed in the first pregnancy. In 75 % of these women, alloimmunization by HPA-1a antigens, however, occurs at delivery, which enables development of antibody-mediated immune suppression to prevent maternal immunization. As for HDN, the recurrence rate of FNAIT is high. For advancing diagnostic efforts and treatment, it is thereby crucial to understand the pathogenesis of FNAIT, including cellular immunity involvement. This review presents the current knowledge on FNAIT. Also described is a program for HPA-1a screening in identifying HPA-1a negative pregnant women at risk of immunization. This program is now performed at the Institute of Hematology and Transfusion Medicine in cooperation with the Department of Obstetrics and Gynecology of the Medical Centre of Postgraduate Education in Warsaw as well as the UiT The Arctic University of Norway.Keywords
This publication has 84 references indexed in Scilit:
- Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteersBlood, 2013
- Compound heterozygosity of HLA‐DRB3*01:01 and HLA‐DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopeniaTransfusion, 2012
- The Development of Severe Neonatal Alloimmune Thrombocytopenia due to Anti-HPA-1a Antibodies Is Correlated to MaternalABOGenotypesJournal of Immunology Research, 2012
- Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic reviewBJOG: An International Journal of Obstetrics & Gynaecology, 2010
- Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programmeBJOG: An International Journal of Obstetrics & Gynaecology, 2009
- HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrityMolecular Immunology, 2009
- Developing recombinant HPA-1a–specific antibodies with abrogated Fcγ receptor binding for the treatment of fetomaternal alloimmune thrombocytopeniaJournal of Clinical Investigation, 2008
- Crystallographic Structure of the Human Leukocyte Antigen DRA, DRB3*0101: Models of a Directional Alloimmune Response and AutoimmunityJournal of Molecular Biology, 2007
- Alloimmunization to Platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3∗0101 and HLA-DQB1∗0201Human Immunology, 1992
- The platelet alloantigen Zwaor PlA1is expressed by cultured endothelial cellsBritish Journal of Haematology, 1987